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introduction: Hypoplastic left heart syndrome (HLHS) is a congenital condition with an 
underdeveloped left ventricle (LV) that provides inadequate systemic blood flow postna-
tally. The development of HLHS is postulated to be due to altered biomechanical stimuli 
during gestation. Predicting LV size at birth using mid-gestation fetal echocardiography 
is a clinical challenge critical to prognostic counseling.
hypothesis: We hypothesized that decreased ventricular filling in utero due to mitral 
stenosis may reduce LV growth in the fetal heart via mechanical growth signaling.
Methods: We developed a novel finite element model of the human fetal heart in which 
cardiac myocyte growth rates are a function of fiber and cross-fiber strains, which is 
affected by altered ventricular filling, to simulate alterations in LV growth and remodeling. 
Model results were tested with echocardiogram measurements from normal and HLHS 
fetal hearts.
results: A strain-based fetal growth model with a normal 22-week ventricular filling 
(1.04  mL) was able to replicate published measurements of changes between mid- 
gestation to birth of mean LV end-diastolic volume (EDV) (1.1–8.3 mL) and dimensions 
(long-axis, 18–35 mm; short-axis, 9–18 mm) within 15% root mean squared deviation 
error. By decreasing volumetric load (−25%) at mid-gestation in the model, which emu-
lates mitral stenosis in utero, a 65% reduction in LV EDV and a 46% reduction in LV wall 
volume were predicted at birth, similar to observations in HLHS patients. In retrospective 
blinded case studies for HLHS, using mid-gestation echocardiographic data, the model 
predicted a borderline and severe hypoplastic LV, consistent with the patients’ late- 
gestation data in both cases. Notably, the model prediction was validated by testing for 
changes in LV shape in the model against clinical data for each HLHS case study.
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inTrODUcTiOn
Hypoplastic left heart syndrome (HLHS), one of the most severe 
congenital heart defects, occurs when the left ventricle (LV) is 
not adequate to provide sufficient blood flow to the systemic 
circulation (1). Despite recent improvements in clinical manage-
ment, HLHS patients face substantial morbidity and mortality, 
with a 1-year transplant-free survival of 64–74% (2–4). The role 
of biomechanics in normal and pathologic cardiac development 
in utero is an understudied topic. Experimental studies suggest 
that perturbations in biomechanical stimuli during development 
can result in HLHS (5–7). The treatment of HLHS can be one 
of the most expensive neonatal diagnoses, so there is a need for 
improved quantitative approaches.
Fetal growth occurs via hyperplasia (cell proliferation by cell 
division) and hypertrophy (enlargement of cell size by addition 
of sarcomeres) and is regulated by developmental stage, growth 
factors, and hemodynamic load (8–11). During early stages of 
gestation, when the cardiac structures are still developing, growth 
is highly regulated by growth factors when hemodynamic load is 
significantly low. However, after 10–14 weeks of gestation, when 
the process of cardiac looping is complete and cardiac chambers 
are fully formed structurally, hemodynamic load is gradually 
increasing and accelerates hypertrophic cardiac growth signifi-
cantly (5, 8).
Several studies have shown that cardiac morphogenesis and 
remodeling adapts in response to changes in biomechanical 
stress or strain (11–16). Experimental studies in isolated cardio-
myocytes have reported sarcomere addition in series or parallel 
leading to cellular hypertrophy in response to mechanical stretch 
(13, 17, 18). Altered loading conditions significantly affect gene 
expression changes at the cellular level via proliferation, mecha-
notransduction, and hypertrophy signaling pathways resulting in 
increased mRNA and changes in cardiomyocyte size and shape 
(8, 19–23). Embryonic sheep, chicken, and zebrafish models with 
decreased ventricular filling also develop ventricular hypoplasia 
(6, 7, 14, 24, 25). Partial LV inflow obstruction in the fetal sheep 
model at mid-gestation resulted in an early form of HLHS within 
7 days of the surgical procedure as a 30% decrease in cardiac out-
put and a 70% decrease in LV/right ventricle ratio was reported 
(6, 13, 16, 26, 27). Additionally, studies have shown that restoring 
blood flow to the LV can “hemodynamically rescue” the chick 
model of HLHS (26, 28–34). Importantly, fetuses with narrowing 
or obstruction of the foramen ovale, mitral valve, or aortic valve 
frequently develop HLHS (35–37).
Based on these observations, it is likely that decreased biome-
chanical load associated with impaired ventricular filling can lead 
to ventricular hypoplasia. Obstruction at the level of the mitral 
valve (stenosis/atresia) or foramen ovale result in decreased 
diastolic filling of the LV. This perturbed filling could result in 
decreased passive stretching of ventricular cardiomyocytes, which 
would alter the biomechanical-mediated signaling response, 
thereby affecting cellular and organ level growth (13, 17, 18, 23). 
Given the limited understanding of the molecular pathogenesis 
of HLHS and the poor outcomes of current treatments, there is 
an urgent need to characterize the effects of abnormal ventricular 
filling and cardiac stretch on embryonic cardiomyocyte growth 
in the ventricle.
Multiscale computational models of LV growth and remodeling 
have been used to provide insight into the morphogenetic process 
of cardiac looping in the embryonic chick heart, cardiac growth 
in the postnatal rat, and the mechanical mechanisms regulating 
cardiac remodeling in the adult heart (26, 28, 30–33, 38–41). 
However, there has been limited use of in silico models to study 
ventricular mechanics and growth in human congenital heart 
disease. While there have been a limited number of simulations 
examining the blood flow patterns in congenital heart disease 
patients (42, 43), there have been no reports of computational 
models of alterations in LV growth and morphogenesis in human 
HLHS.
Computational growth modeling of healthy and diseased 
human fetal hearts requires structural and functional measure-
ments that can accurately elucidate physiological behavior of the 
heart (28, 31, 44). These data can provide unique information in 
the fetal heart including the 3D geometry, mechanical param-
eters, and clinical measures of function. To build an accurate 
computational model, reliable clinical and experimental meas-
urements are necessary at various fetal developmental stages. 
To contextualize the findings of disease models and to identify 
the functional differences from a normally developing heart, it is 
critical to first understand and characterize the growth behavior 
and mechanical properties of a normal human fetal heart under 
varying physiological conditions. Therefore, we developed a 
single ventricle model of an average-sized human fetal heart 
to calibrate a normal strain-dependent growth law to serve as 
a reference model. We sought to understand and quantify the 
effect of mechanical loads on human fetal ventricular growth 
using patient-specific computational models of HLHS patients 
derived from fetal echocardiograms. Specifically, based on the 
experimental observation that cardiac myocytes hypertrophy in 
response to stretch as a stimulus (13, 45, 46), we test the hypoth-
esis that reduced ventricular filling observed at end-diastole can 
predict reduced ventricular growth in HLHS patients with an 
etiology of inadequate mitral valve patency. Computer-aided 
conclusion: Reduced ventricular filling and altered shape may lead to reduced LV 
growth and a hypoplastic phenotype by reducing myocardial strains that serve as a 
myocyte growth stimulus. The human fetal growth model presented here may lead to a 
clinical tool that can help predict LV size and shape at birth based on mid-gestation LV 
echocardiographic measurements.
Keywords: hlhs, growth hormone, biomechanics, sarcomeres, computational model, patient-specific modeling, 
mechanobiology
FigUre 1 | (a) Flowchart of left ventricle (LV) fetal growth model. Normative data from fixed fetal hearts were used to construct the unloaded LV geometry at 
22 weeks. This geometry was inflated to LV end-diastolic pressure; the passive material properties were adjusted to match the LV dimensions and cavity volume. 
Growth simulations were then performed to obtain the new LV end-diastolic geometry at each time step. The growth constants were then adjusted to match the LV 
volumetric growth. The growth in the geometry was validated by comparing the resulting LV end-diastolic dimensions with the dimensions obtained from normal 
fetuses using echocardiography. (B) Graphical representation of the sarcomere addition in series and parallel. Axial strain leads to sarcomere addition in series, 
which translates to circumferential growth in the LV model. Transverse strain leads to sarcomere addition in parallel, which translates to longitudinal and wall 
thickness growth in the LV model.
3
Dewan et al. Fetal Growth Model of HLHS
Frontiers in Pediatrics | www.frontiersin.org February 2017 | Volume 5 | Article 25
diagnostics employing predictive patient-specific models of fetal 
ventricular growth in HLHS could allow for improved prenatal 
counseling and potential early selection of candidates for in utero 
interventions.
MaTerials anD MeThODs
Model Development Framework
We developed a computational model of human fetal LV growth 
using the framework of a previously established strain-based 
growth law (26, 32) (Figure 1). The human LV fetal growth model 
uses a finite element (FE) model of LV geometry with empirical 
myocardial material properties adjusted to match the human fetal 
ventricular measurements at mid-gestation in normal hearts. 
Experimentally measured LV dimensions were used to generate a 
FE mesh in a prolate spheroidal coordinate system for describing 
the ellipsoidal nature of the heart: a thick-walled truncated ellip-
soidal shell bounded by inner and outer surfaces. Twenty-four 
different FE models of idealized LV fetal geometry at 22 weeks 
of gestation were constructed to optimize the normal fetal LV 
growth model (Data Sheet S1 in Supplementary Material). The 
idealized LV geometry was selected based on retrospective error 
analysis and computation of the least cumulative error for all 
constraining model parameters and LV shape during growth. The 
best-fit FE model was used as the reference model for growth 
simulations.
Unloaded Fetal lV geometry
In order to develop the human fetal growth model, we created a 
FE mesh of the unloaded LV that matches fetal LV dimensions 
obtained from median dimensions of 14 formalin-fixed human 
fetal hearts at 22 weeks of gestation (47). Based on the median 
dimensions, we constructed 24 idealized LV geometries in prolate 
spheroidal coordinates with 4 radial (endocardium to epicardium) 
and 5 longitudinal (apex to base) elements. The axisymmetric LV 
FE mesh used for the simulations consisted of 30 nodes, 20 FEs 
(5 longitudinal, 4 transmural, and 1 circumferential) with cubic 
4Dewan et al. Fetal Growth Model of HLHS
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Hermite basis functions for all prolate spheroidal coordinates 
in the transmural (λ) and longitudinal (μ) directions and linear 
basis functions for all coordinates in circumferential direction 
(φ). Cardiomyocyte fiber angles were then incorporated into the 
model by assigning an inplane angle of −37° (relative to circum-
ferential) at the epicardium, and 83° at the endocardium, with a 
linear variation across the ventricular wall (48, 49).
end-Diastolic Fetal lV geometry
We obtained the end-diastolic fetal LV geometry by passively 
inflating the unloaded LV mesh. In order to model the resting 
properties of the myocardium, we make use of the transversely 
isotropic form of the constitutive model developed by Guccione 
et al. (50) (Methods S1 in Supplementary Material). The passive 
material properties of the myocardium were adjusted such that 
the end-diastolic fetal LV geometry was constrained by clini-
cally measured median values of end-diastolic volume (EDV) 
(51), EDP (52), and LV dimensions (inner length and diameter) 
(47, 53) corresponding to 22  weeks of gestation (Table S1 in 
Supplementary Material).
growth Model
The inflated mesh was then set to grow from mid-gestation to 
birth at a constant EDP with the parameters listed (Methods 
S2 and Table S2 in Supplementary Material). Briefly, our group 
previously developed a strain-based volumetric growth model 
that deforms the stress-free tissue configuration B0 to a grown 
configuration Bg, which will generally not be stress free (Methods 
S2 in Supplementary Material) (32). The biomechanical stimuli 
for growth in these models are derived from maximal strains. The 
growth deformation gradient tensors are defined with respect to 
the local fiber orientation (with component Fff in the fiber direc-
tion, component Fcc in cross-fiber direction parallel to the wall, 
and Frr the radial component, perpendicular to the two former), 
which allows for the definition of a transversely isotropic growth 
tensor (54).
geometric Model Optimization
Twenty-four unique FE model geometries were constructed. All 24 
FE model geometries have been listed with their parameter values 
and explicitly shown in Data Sheet S1 in Supplementary Material. 
These geometries were constrained by the median values of (a) ex 
vivo unloaded fetal LV dimensions of LV length or long-axis (LA), 
LV diameter or short-axis (SA), and LV wall thickness (WT), as 
measured by morphometric analysis of 14 fixed hearts (47); (b) 
end-diastolic LV geometry (LA and SA) as measured by echocar-
diography (53); and (c) clinical measures of end-diastolic func-
tion (EDP and EDV) as measured by in utero catheterization (52) 
and echocardiography, respectively (51), at 22 weeks of gestation 
(Data Sheet S1 in Supplementary Material). The 24 LV geometries 
were constructed such that each FE model was unique with vari-
ous combinations of values of the seven constraining parameters 
(unloaded LV LA, LV SA, and LV WT dimensions, EDP, EDV, 
LV LA, and LV SA dimensions at end-diastole, at 22 weeks). Each 
FE model had to satisfy the condition that every constraining 
parameter is within the reported measurement/clinical range for 
that parameter. The idealized LV geometry was selected based 
on retrospective error analysis of each model (Methods S3 in 
Supplementary Material). Error analysis was done by computing 
cumulative z-scores for each model, such that each model was 
fitted to the mean of aforementioned seven constraining model 
parameters and mean of LV shape growth at incremental time 
points from mid-gestation to birth. The larger the deviation of the 
model values from the mean values, the higher the error value for 
the model. For every model, individual z-scores were calculated 
for all model parameters, i.e., clinical measures of unloaded 
shape, loaded shape, EDV, and EDP at 22 weeks of gestation, and 
for LV shape from mid-gestation to term. Individual z-scores of 
all parameters and LV shape growth were summed up for each 
model to compute the cumulative z-score corresponding to the 
model (see Tables 1 and 2). The model with the lowest cumulative 
z-score was selected as the optimum fetal model.
Model simulations
The FE model developed in this study was numerically solved 
using Continuity 6.4, a problem-solving environment for multi-
scale modeling of cardiac biomechanics and electrophysiology. 
It is distributed free for academic research by the National 
Biomedical Computation Resource and can be downloaded at 
http://www.continuity.ucsd.edu/Continuity.
The different steps in performing the growth simulations 
are shown in Figure  1. The unloaded fetal LV geometry was 
inflated to the end-diastolic pressure to obtain the starting LV 
end-diastolic geometry at 22  weeks of gestation. The growth 
simulations were then performed by repeatedly applying the 
growth laws to this end-diastolic geometry to directly compute 
the grown end-diastolic geometry at each time step. Once the 
growth simulations were performed, the growth time step that 
accounts for rate of growth was adjusted to match the normative 
EDV growth. These growth constants were then kept the same for 
all subsequent simulations for the different cases.
The non-linear FE models were solved with a modified 
Newton-Raphson iteration scheme. Integration was performed 
with 3 ×  3 ×  3 Gaussian quadrature points. Convergence was 
reached when both the sum of incremental displacements and 
the sum of the residuals were lower than 10−3 mm and 10−5 N, 
respectively. The Jacobian was calculated and factorized in the first 
iteration of a new time step and when the solution was diverging. 
The system of linear equations was solved using SuperLU (55). 
Boundary conditions in the models were such that the apex was 
only allowed to move along the LV LA, the base was constrained 
in longitudinal direction, and the epicardium of the base was 
constrained in circumferential direction.
Model fits to experimental data were evaluated based on 
standard error from the data mean or root mean squared devia-
tion (RMSD) from the regression line of the experimental data. 
The RMSD is calculated using the following formula,
 RMSD=
model regression
data
V V
n
−( )∑ 2  
where Vmodel is the model-predicted EDV, Vregression is the EDV 
calculated using the exponential regression fit to the data, and 
ndata is the number of data points.
TaBle 1 | z-scores for geometry and function model parameters at the unloaded and loaded state prior to growth, and cumulative z-scores for each 
dimension during growth from 22 to 40 weeks of gestational stage.
Pregrowth (22 weeks) Postgrowth 
(22–40 weeks)
Model Unloaded dimensions loaded 
dimensions
end diastolic volume eDP Dimensions
short-axis (sa) long-axis (la) Wall thickness sa la sa la
1 0.26 0.24 4.08 1.15 1.13 1.62 1.09 5.55 5.88
2 1.77 1.35 3.55 2.46 0.16 0.75 1.09 24.35 10.72
3 0.28 1.30 1.40 1.28 0.04 1.95 1.09 20.24 18.52
4 0.28 1.26 5.05 1.33 0.08 1.94 1.09 8.90 21.87
5 3.28 0.74 1.27 3.77 0.85 1.25 1.09 44.51 12.29
6 4.83 0.64 2.91 5.02 0.99 2.25 1.09 67.86 5.60
7 2.53 0.74 2.04 3.16 0.70 0.40 1.09 32.38 6.80
8 3.24 0.19 1.43 3.71 1.38 1.66 1.09 43.98 9.39
9 1.74 0.19 1.84 2.44 1.22 0.20 1.09 22.56 8.51
10 1.78 0.74 0.10 2.52 0.63 0.46 1.09 21.76 9.81
11 1.46 0.43 2.03 2.21 0.95 0.63 1.09 18.48 5.32
12 2.67 0.37 0.81 3.25 0.63 0.55 1.09 34.72 9.71
13 2.21 0.38 0.21 2.88 1.01 0.11 1.09 27.73 9.56
14 1.93 0.74 0.06 2.65 0.64 0.32 1.09 23.87 9.31
15 2.22 0.74 1.94 2.90 0.68 0.09 1.09 28.16 8.57
16 1.74 0.24 3.76 2.41 1.33 0.02 1.09 23.92 5.24
17 1.18 0.99 0.28 0.53 0.39 0.72 0.74 14.99 9.73
18 0.59 0.79 0.30 1.83 0.67 0.71 0.74 7.11 8.19
19 0.29 0.88 0.39 1.57 0.57 0.80 0.74 12.37 4.21
20 0.29 1.02 0.33 1.58 0.44 1.05 0.74 6.95 8.69
21 0.29 0.96 0.38 1.56 0.49 1.06 0.74 8.41 6.68
22 0.06 0.88 0.36 1.55 0.57 1.03 0.74 9.40 5.11
23 0.00 0.96 0.38 1.32 0.49 0.97 0.74 5.44 6.71
24 0.00 0.84 0.42 1.30 0.62 0.95 0.74 5.29 5.25
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clinical cases explored by Model
Once the baseline parameters of the growth model were deter-
mined, various growth cases were simulated to determine the 
effect of volumetric filling, preload, material properties, and 
shape, on the LV growth. To determine the effect of ventricular 
filling on growth, the same unloaded geometry was inflated to 
different preloads by changing the end-diastolic pressure while 
keeping the material properties constant, and then the growth 
simulations were performed during which pressures were 
maintained.
To quantify the effect of ventricular shape and WT on fetal 
growth, the reference FE model shape was modified by either 
changing SA to LA ratio or average WT of the LV, prior to infla-
tion. To achieve this, four unloaded geometries were constructed 
with the same initial volume as the normal unloaded geometry. 
Two geometries were developed by changing the location of the 
epicardium nodes uniformly along the LV to yield a thick-walled 
LV (thick; WT: +30%) and a thin-walled LV (thin; WT: −30%) 
relative to normal. The other two were developed by manipulat-
ing the overall shape of the LV to yield “TallNarrow” (LA:SA: 
+20%) and “ShortWide” (LA:SA: −20%) geometries. The four 
geometries were then inflated at a (a) constant preload of 0.75 kPa 
and (b) constant end-diastolic filling volume relative to unloaded 
(EDV-V0) of 383 µL.
Patient-specific simulations
The fetal echocardiograms were conducted in the Pediatric 
Cardiology Division of Rady Children’s Hospital, San Diego, and 
Primary Children’s Hospital, Utah, following standard guidelines 
set by the American Society of Echocardiography. All patient data 
were retrospectively collected and de-identified. Measurements of 
the hypoplastic LV were made retrospectively from the recorded 
echocardiogram clips. Measurements were made in the four-
chamber view of the LV internal and external diameters (width) 
at the base and mid-level, as well as the inner and outer length of 
the cavity only when the image quality allowed clear definition of 
the endocardium and epicardium.
Two case studies of HLHS patients were evaluated. The 
patient-specific FE models were constructed using end-diastolic 
LV dimensions measured at first clinical time point of study 
(23.1 and 31  weeks of gestation, respectively). The unloaded 
geometry was computed using the same material parameter 
values as the normal fetal heart using the methods described 
by Krishnamurthy et  al. (49). Growth simulations were then 
performed using the reference growth model parameter values 
and the LV EDV at second clinical time point of study (30 and 
39.1  weeks, respectively) was computed. The predictions from 
the growth simulations were then independently tested by com-
paring the simulated LV end-diastolic dimensions at the second 
TaBle 2 | cumulative z-scores for the model geometries pre- and 
postgrowth with the minimum cumulative z-score highlighted in blue, 
representing the selected model geometry for reference normal human 
fetal growth model.
Model cumulative z-score
Pregrowth Postgrowth Total
1 9.57 11.43 21.01
2 11.12 35.07 46.19
3 7.33 38.76 46.09
4 11.03 30.77 41.80
5 12.24 56.81 69.05
6 17.72 73.46 91.18
7 10.65 39.18 49.83
8 12.70 53.37 66.07
9 8.71 31.07 39.78
10 7.32 31.57 38.89
11 8.80 23.80 32.59
12 9.37 44.42 53.79
13 7.88 37.29 45.17
14 7.42 33.17 40.60
15 9.67 36.73 46.40
16 11.47 29.16 40.63
17 4.84 24.72 29.56
18 5.63 15.29 20.93
19 5.24 16.58 21.82
20 5.46 15.63 21.09
21 5.47 15.09 20.56
22 5.19 14.51 19.71
23 4.87 12.16 17.03
24 4.87 10.55 15.41
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clinical time point of study with echocardiographic measure-
ments for the same.
resUlTs
human Fetal lV reference Model
Upon z-score analysis of all geometric models constructed (Data 
Sheet S1 in Supplementary Material), Model 24 resulted with the 
lowest cumulative z-score and was chosen as the working refer-
ence human fetal LV model for normal growth (Tables 1 and 2). 
The geometry of the unloaded FE mesh for the optimum model 
at mid-gestation (Figure  2A) was within the experimentally 
reported values of fixed LV hearts at 22 weeks of age (Figure 2B). 
At end-diastole, the working reference fetal LV model geometry 
fit at the high-end of the normal clinical range of reported values 
for LV length and LV diameter (Figure 2C), albeit at the median 
of clinical values of EDP (5.63  mmHg) and EDV (1.02  mL) 
(Figures 2D,E).
human Fetal lV growth Model from Mid-
gestation to Birth
Normal fetal LV growth is quantified from mid-gestation to term 
and quantified as volumetric and shape growth of the LV cavity 
and wall. Simulating fetal growth from mid-gestation to birth 
in the reference human fetal LV model replicated the measured 
end-diastolic LV cavity volume (Figures 3A,C) and LV geometric 
dimensions (Figure  3B), and LV wall volume (Figure  3D) to 
within 15% RMSD error based on echocardiographic measure-
ments (53, 56–61), in both forward and reverse directions, during 
the third trimester of pregnancy. Specifically, the RMSD between 
the model-predicted EDV and the exponential regression fit to 
the EDV data is 0.89 mL. The maximum deviation occurred at 
40  weeks, where the percentage of RMSD with respect to the 
range of data is 13.4%. The RMSD between the model-predicted 
SA diameter and the linear regression to SA data is 0.606 mm, and 
the RMSD between the model-predicted LA lengths to the linear 
regression to the LA data is 1.126 mm. The maximum deviations 
from data occurred at 22 weeks in both cases and were within 0.55 
and 0.61 SDs, respectively. The model was able to accurately predict 
the physiological unloaded state of the LV at around 12–14 weeks 
(Figure 3C). However, greater deviation from clinical values is 
observed for LV wall mass during forward and reverse growth for 
early-fetal (0–14 weeks) growth (Figure 3D). The RMSD between 
the model-predicted LV wall mass and the exponential regression 
to the four different data sets were computed to be 0.99 mL (60), 
1.11 mL (57), 1.14 mL (59), and 1.25 mL (58), respectively.
human Fetal lV growth Model sensitivity 
to eDV
In fetal echocardiograms, patients with narrowing or obstruction 
of the foramen ovale, mitral valve, and/or aortic valve frequently 
develop HLHS. Fetal sheep, chicken, and zebrafish models with 
decreased ventricular filling also develop ventricular hypoplasia 
(6, 14, 46). Decreasing the ventricular filling volume in the refer-
ence normal growth FE model at 22  weeks, while keeping the 
material properties of LV constant (Figure 4A), resulted in drastic 
decreases in LV cavity volume (Figure 4B) and LV wall volume 
(Figure 4C) during fetal LV growth from mid-gestation to birth. 
Simulated growth of a hypoplastic LV (reduced  ventricular  filling) 
(−25%) resulted in significant reduction in LV EDV (−65%) and 
LV wall volume (−46%) at birth (Figures 4B,C). A linear correla-
tion was determined between LV filling volume and LV cavity 
growth/LV wall growth (Figure 4D). Every 10% decrease in LV 
filling volume at mid-gestation resulted in a 25% decrease in LV 
cavity volume and 17% decrease in LV wall volume at birth in the 
reference model.
human Fetal lV growth Model sensitivity 
to lV shape
Patient-specific changes in LV shape, as observed routinely during 
clinical investigations, can result in deviations from the idealized 
LV growth and might be prognostic of HLHS phenotype (62). 
Modifying the reference FE model while maintaining constant 
initial volume, preload, LV filling volume (EDV-V0), and material 
properties (Figure 5A) showed that that thin-walled ventricles 
grew larger in size and volume than the equivalent thick-walled 
models (Figure 5B). The effects of changing ventricular length-
to-width ratio (Figure  5A) while holding other properties 
constant were comparatively small. However, the ShortWide LV 
did grow more than the TallNarrow model (Figure 5B). A steep 
inverse linear correlation was determined between LV WT and 
LV cavity growth (Figure 5C). Every 10% increase in LV WT at 
mid-gestation resulted in a 6.8% decrease in LV cavity volume at 
FigUre 2 | (a) Rendered finite element (FE) mesh of unloaded human fetal left ventricle (LV) at 22 weeks of gestational age depicting the four transmural LV wall 
elements (epicardium to endocardium shade gradations), the five longitudinal elements from apex to base (cross-sectional discs), transmural helical fiber angles from 
+83° to −37° (endocardium to epicardium; color-mapped sprites) w.r.t. circumferential direction and mesh dimensions for LV inner length, LV inner diameter, and LV 
wall thickness. (B) Bar graph showing comparisons for unloaded LV dimensions between morphometric measurements (white bars) from fixed fetal hearts (47) and 
FE mesh (black bars) at 22 weeks of gestational age. (c) Fitting of simulated LV end-diastolic model geometry (black bars) against echocardiographic measures of 
LV dimensions (white bars) (53) at 22 weeks of gestational age. Simulation set points (solid red dot) of EDP (D) and end-diastolic volume (EDV) (e) from human 
patient data as measured by fetal cardiac catheterization (52) and echocardiography (51), respectively, at 22 weeks of gestational age.
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birth. Also, a shallow inverse linear correlation was determined 
between LV LA:SA ratio and LV cavity growth (Figure  5C), 
wherein, a 10% increase in LA:SA ratio at mid-gestation resulted 
in a 2% decrease in LV growth at birth.
Patient-specific human Fetal lV growth 
Model case study 1
In a blinded case study, using echocardiographic data (for LV 
geometry) from a severely hypoplastic fetus at 23.1 weeks as the 
input, we constructed a patient-specific FE model (Figure 6A). 
The patient-specific FE model was in good agreement with 
the echocardiography data with highest variability in WT 
dimension from apex to base (Figure 6A). At end-diastole, the 
current patient-specific model presented with a significantly 
lower ventricular filling volume at 0.187  mL, decreased LA:SA 
ratio at 1.2, and decreased WT relative to a normal healthy 
LV (Figure  6B). Based on our previous analysis of the refer-
ence model, the patient-specific case was predisposed to faster 
growth as a function of altered geometry (thinner wall and lower 
LA:SA). In contrast, the patient-specific case was predisposed to 
much slower growth as a function of lower ventricular filling. 
The simulated growth of the patient-specific model predicted a 
severely hypoplastic LV at birth, consistent with the patient diag-
nosis (Figure 6C). The patient-specific growth model predicted 
a consistent match in the observed reduction in the measured 
LV cavity volume (Figure  6C) and end-diastolic LV geometric 
dimensions (Figure  6D) at 30.1  weeks, to within 15% clinical 
error based on echocardiographic measurements.
Patient-specific human Fetal lV growth 
Model case study 2
In a blinded case study, using echocardiographic data (LV 
geometry) from a borderline hypoplastic fetus at 31  weeks as 
the input, we constructed a well-matched patient-specific FE 
model (Figure  7A). At end-diastole at 31  weeks, the patient-
specific model had a significantly lower ventricular filling 
volume, increased LA:SA ratio, and increased WT relative to a 
normal healthy LV (Figure 7B). Based on our previous analysis 
FigUre 3 | (a) Simulated normal human fetal left ventricle (LV) volumetric growth (solid black trace) fitted to normal fetal echocardiographic measures of end-
diastolic volume (EDV) (solid black circles) (51) from onset of third trimester of pregnancy (22 weeks of gestational age) to birth (40 weeks of gestational age).  
(B) Validation of simulated LV length (solid black trace) and LV diameter (solid red trace) against clinical echocardiographic measures (dotted lines) (53). Validation of 
simulated LV EDV (c) and LV wall volume (D) in forward (solid black line) and reverse (black dotted line) against multiple clinical data sets.
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of the reference model, the patient-specific case was predis-
posed to slower growth as a function of both altered geometry 
(thicker wall and higher LA:SA) and lower ventricular filling. 
The simulated growth of the patient-specific model predicted a 
borderline hypoplastic LV at birth, consistent with the patient 
diagnosis (Figure  7C). The patient-specific growth model 
predicted a consistent match between the measured LV cavity 
volume (Figure 7C) and end-diastolic LV geometric dimensions 
(Figure 7D) at 39 weeks, to within 15% clinical error based on 
echocardiographic measurements.
DiscUssiOn
In this study, we quantitatively investigated, in silico, the effect of 
reduced ventricular filling at end-diastole, in patient-specific mod-
els of HLHS, on LV fetal growth. A novel FE growth model of the 
healthy human fetal LV, using a previously described strain-based 
growth law, with idealized average geometry at mid-gestation 
using clinical data, has been presented as a reference human fetal 
LV growth model from mid-gestation to birth. Model prediction 
results from the two blinded case studies of HLHS patients are in 
good agreement with the clinically observed values for LV cavity 
volume growth and shape changes. To our knowledge, this is the 
first study to attempt to investigate the biomechanical relation-
ship between LV filling at end-diastole and LV ventricular growth 
in human fetal hearts with HLHS. The human fetal growth model 
presented here is a significant step toward the development of a 
clinical tool that may be used to predict LV size and shape at birth 
based on mid-gestation LV filling.
computational Models of Fetal growth 
and hlhs
The specific biomechanical stimuli that trigger cardiac growth 
are not completely understood. There is general agreement in the 
field that an increase in stress or strain at organ level and/or cel-
lular level leads to a growth response in the heart (13, 16, 26–28, 
30–34). Most cardiac growth models have been formulated, 
wherein growth is regulated by changes in mechanical stress and/
or strain (13, 16, 26, 27). These computational models are based 
on the experimental observation that at the organ level, volume 
overload or pressure overload triggers eccentric or concentric 
hypertrophy, respectively, via changes in regional wall stresses 
and strains (13, 16, 26–28). Peña et  al. constructed simplified 
ellipsoidal meshes of the human fetal heart from in vivo echo-
cardiographic measurements at different gestational ages, which 
were then used to optimize for the material properties using FE 
analysis (28). However, they did not directly apply a growth law. 
They found that while the active tension of the models increased 
with gestational age, there was not a significant change in the pas-
sive material properties. Ohayon et al. used a global stress-based 
growth law applied directly to the unloaded geometry to simulate 
global human fetal LV growth (26, 28, 32). Though able to predict 
the growth of the fetal LV, this model is not based on sarcomere 
addition along the fiber and cross-fiber direction that happens 
FigUre 4 | (a) Passive inflation of unloaded left ventricle (LV) reference finite element model to varying ventricular filling volumes by varying ventricular loading. 
Simulated LV cavity volume (B) and LV wall volume (c) growth under varying ventricular filling conditions. (D) Relationship between ventricular filling and LV cavity 
volume and LV wall volume growth in the reference model.
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in cardiac growth. In this model of fetal growth, interpreting the 
direct effects of stresses and strains along the local fiber directions 
on LV growth are difficult as global growth has be transformed to 
the local fiber directions.
The changes in LV WT are mediated by cellular remodeling 
of cardiomyocytes via sarcomere addition in series or parallel. 
We applied a previously described strain-dependent growth law 
acting locally at each gauss point based on the fiber and cross-
fiber strains, which has been used to describe both eccentric 
and concentric remodeling in dogs and neonatal rat growth, in 
our fetal heart model (31, 51, 52, 56, 61). Earlier studies have 
reported a monoexponential increase in fetal LV EDV and a 
linear increase in fetal systolic and diastolic pressures during the 
course of human gestation (26, 32, 63). Thus, it would suggest that 
fetal heart growth is largely driven by volume overload as the bio-
mechanical stimuli. Accordingly, growth in our model is driven 
via maximal fiber and cross-fiber strains at each gauss point. In 
addition, decrease in ventricular flow is routinely documented in 
the experimental models and clinical studies of HLHS.
The single ventricle model for normal fetal growth is a sig-
nificant step toward building subject-specific models based on 
fetal echocardiography data. To the best of our knowledge, this is 
the first computational model that describes LV growth behavior 
in the human fetus by integrating information on LV geometry 
and function from multiple clinical measurements and predicts 
patient diagnoses based on mid-gestation echocardiographic 
geometry. Our fetal human growth model is based on ideal-
ized LV geometry at mid-gestation and is able to replicate the 
later-gestation fetal LV volumetric and geometric growth (size 
and shape) observed clinically with less than 15% error. Fetal 
LV dimensions obtained from retrospective echocardiographic 
images are valuable measurements as they provide routine clini-
cal information about ventricular structure in HLHS patients 
(49, 51, 52, 56, 61). Fetal ventricles are of smaller scale relative 
to adult ventricles, which compounds the difficulty of taking 
accurate measurements from echocardiography, especially for 
LV WT measurements. This was reflected in the significant vari-
ation within the four experimental data sets of fetal LV wall mass 
(57–60). All four data sets employed different experimental tech-
niques to acquire data that would have led to technical variability 
within these data. Of the four data sets for WT, our model was 
able to match the results of only one data set within acceptable 
FigUre 5 | (a) Representations of the shape modifications of the reference finite element model by either changing short-axis (SA) to long-axis (LA) ratio or average 
wall thickness (WT) of the left ventricle (LV), prior to inflation. (B) Simulated LV cavity volume growth under varying LV shapes. (c) Relationship between LV shape 
changes and LV cavity volume growth in the reference model.
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values (60). Notably, St John Sutton et  al. was the only group 
to compare their in  vivo measurements to explanted LV mass 
measurements (60). More validation with serial data consisting 
of paired measurements for LV dimensions (LA, SA, and WT) 
will be required to improve model results given the scatter in 
data. This becomes pertinent as LV growth is strongly influenced 
by WT in our model.
Patient-specific human Fetal lV growth 
Model case studies
In case of subject-specific data obtained from echocardiograms 
of fetuses diagnosed with HLHS, measurements were only 
made when the structures were visibly clear and delineated. 
Nonetheless, there is the possibility of introducing error due to 
intraobserver variability. Additionally, error can be greater in 
hypoplastic LV measurements due to their smaller LV size rela-
tive to normally developing LV. In order to assess LV geometry 
accurately for these case studies, six geometric measurements 
of LV dimensions were provided at different LV planes from 
apex to base from the 2D echocardiogram four-chamber view. 
For both patient-specific cases, model predictions matched the 
clinical data for LV EDV and shape reasonably well. Specifically, 
the model predicted the shape better for the borderline HLHS 
case than the severe HLHS case. Interestingly, the biggest 
discrepancy in shape results for the borderline HLHS case was 
observed in the LV WT growth. Additionally, the prediction for 
EDV was much better for the severe HLHS case than for the 
borderline HLHS case. Nonetheless, in both cases, the model 
was able to predict the clinical diagnosis of the fetal subject. 
Ideally, using MRI data and LV inflow, data would allow for 
more constraints on the developed mesh and, therefore, a more 
faithful patient-specific geometry. However, early-fetal MRI is 
a developing field and not a routine clinical procedure as yet. 
Additionally, LV inflow data were not available for the current 
case studies. Also, measurements at more than two time points 
would be valuable in validating the patient-specific model and 
its predictive capability. In future studies, protocols need to be 
developed to ensure consistent methods between patients and, if 
possible, reduce manual error by having multiple experts obtain 
measurements.
It is noteworthy that the ventricular geometry was imaged at 
end-diastole when the heart experiences a significant amount 
of load. An unloading algorithm developed by Krishnamurthy 
et al. was used to predict the unloaded configuration of the 3D 
FE model under normal preload and passive material properties, 
which may not hold true for the patient-specific case (49). This 
unloaded LV configuration is important computationally and 
biomechanically, as it serves as the reference unstressed state for 
calculation of the developed strains in the model. However, the 
predicted unloaded geometry is able to successfully deform to 
the measured end-diastolic geometry, demonstrating promising 
results. Repeating this with a larger set of patients would serve to 
FigUre 6 | (a) Rendering of the patient-specific mesh at end-diastole, generated based on echocardiographic data obtained at 23.1 weeks. Bar graph showing 
the morphometric match between echocardiographic data (white bars) and patient-specific finite element (FE) model (black bars) at 23.1 weeks. (B) Comparison of 
model shape and ventricular filling between reference FE model of healthy fetal left ventricle (LV) model (white bars) and patient-specific LV model (black bars).  
(c) Simulation of LV cavity growth in patient-specific model (black dotted line) and its comparison to clinically observed growth for the patient (open triangles) and 
normal LV growth (solid circles and solid line). (D) Bar graph showing the morphometric match between echocardiographic data (white bars) and patient-specific FE 
model (black bars) at 30.1 weeks.
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validate the algorithm as well as the ability of the growth model 
to predict dimensions at a future time point.
In addition to ventricular filling at EDV, altered shape plays 
a significant role in altering local strain distribution contribut-
ing to LV growth in our model. A greater understanding of 
the strain distribution experimentally may shed insight into 
the mechanism underlying the significant wall thickening 
observed in hypoplastic hearts. Earlier studies report variable 
systolic strain distribution in hemodynamic chick model of 
HLHS (28, 49). Further investigation into the role of LV shape 
and diastolic strain distributions along with myocardial passive 
material properties is merited to fully comprehend mechanisms 
underlying HLHS. We quantified the effect of both shape 
and ventricular filling on LV growth in our model. Once the 
patient shape is accounted for by using echocardiography data, 
then based on volumetric filling and shape changes, one can 
attempt to predict normal and hypoplastic LV growth by using 
our model. In the future, it would be invaluable to generate a 
biventricular mesh of the fetal heart with fetal circulation in 
order to improve the physiological relevance of the model as 
well as understand the interactive effects between the ventricles 
in a normal and diseased state. This would be specifically useful 
in a clinical case such as HLHS where the right ventricle often 
compensates for the compromised structure and function of 
the LV.
Model assumptions and limitations:
 (a) The simplified ellipsoid shape of the LV used for the reference 
normal model of fetal growth represents an idealized geom-
etry of the LV. Even in “patient-specific” cases, the FE model 
is a simplified axis-symmetric representation of the actual 
LV geometry derived from six-planar measurements of 2-D 
echocardiography in the four-chamber view. However, the 
volume calculations and shape calculations based on this LV 
geometric approximation match the clinical data reasonably 
well.
FigUre 7 | (a) Rendering of the patient-specific mesh at end-diastole, generated based on echocardiographic data obtained at 31 weeks. Bar graph showing the 
morphometric match between echocardiographic data (white bars) and patient-specific finite element (FE) model (black bars) at 31 weeks. (B) Comparison of model 
shape and ventricular filling between reference FE model of healthy fetal left ventricle (LV) model (white bars) and patient-specific LV model (black bars).  
(c) Simulation of LV cavity growth in patient-specific model (black dotted line) and its comparison to clinically observed growth for the patient (open triangles) and 
normal LV growth (solid circles and solid line). (D) Bar graph showing the morphometric match between echocardiographic data (white bars) and patient-specific FE 
model (black bars) at 39 weeks.
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 (b) The FE model assumes an initial stress-free state of the 
myocardium and residual stresses are not factored in. 
More human fetal data are needed to substantiate these 
assumptions.
 (c) In fetal heart growth, cell proliferation substantially contrib-
utes to cardiac growth (24, 44, 64). Studies in animal models 
of sheep have attempted to quantify the contribution of 
hyperplasia to cardiac growth and shown that this decreases 
significantly during the third trimester of pregnancy. 
However, these data and the kinematics of this process, spe-
cifically in human fetal hearts, still remain to be elucidated.
 (d) We assume that there is no change in passive material prop-
erties during growth. An earlier study by Peña et al. supports 
this (28).
 (e) The kinematics of LV growth allows the radial displacement 
of the base while the apex is free to move.
 (f) Growth of the heart is mediated by loading and biome-
chanical tissue strain, without other stimuli such as growth 
hormones.
clinical Perspective
Hypoplastic left heart syndrome can be diagnosed by fetal 
echocardiography between 18 and 22 weeks of gestation (44, 64, 
65). However, borderline cases of HLHS can go undetected in 
many early to mid-gestation fetal exams. Studies have reported 
that neonates with prenatal diagnosis of HLHS show improved 
hemodynamic stability in addition to providing the opportunity 
to plan management and counseling for the family (64, 65). 
Patient-specific computational modeling of developing fetuses 
with HLHS could serve to improve prenatal diagnosis by provid-
ing insight into the biomechanics and growth behavior of the 
affected ventricle. The methods developed in this study aim to 
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facilitate understanding of fetal growth behavior undergoing 
normal development and provide a benchmark model for nor-
mal growth in the human fetal LV, enabling comparison with 
patient-specific fetal LV models. Ultimately, with further testing 
and refinement, the model has potential to aid a clinician in 
counseling, surgical planning, and management of HLHS with 
consideration of rescue options for borderline cases of HLHS.
cOnclUsiOn
The human fetal growth model is a novel tool that may be used 
to understand biomechanical mechanisms underlying HLHS and 
ultimately quantitatively predict the degree of LV hypoplasia to 
potentially guide timing of clinical intervention aimed at rescuing 
the hypoplastic LV in HLHS patients.
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